Euthymics Bioscience Receives $24,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=81f1b07e-bf5a-441d-880b-e461bb098f5f&Preview=1 - Date
7/22/2010 - Company Name
Euthymics Bioscience - Mailing Address
35 Braintree Hill Office Park Braintree, MA 02184 - Company Description
Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment. - Website
http://www.Euthymics.com - Transaction Type
Venture Equity - Transaction Amount
$24,000,000 - Transaction Round
Series A - Proceeds Purposes
The initial Series A proceeds were used to complete the acquisition of DOV Pharmaceutical, Inc. and allow for the continued development of DOV’s unique antidepressant, EB-1010 (formerly known as DOV 21,947), for patients who do not respond adequately to selective serotonin reuptake inhibitors, or SSRIs. - M&A Terms
- Venture Investor
Novartis Venture Fund - Venture Investor
Venture Investors - Venture Investor
Hambrecht & Quist Capital Management - Venture Investor
GBS Venture Partners
